Teriparatide oral - Entera Bio

Drug Profile

Teriparatide oral - Entera Bio

Alternative Names: EP-101 - Entera Bio; Parathyroid hormone oral - Entera Bio; Parathyroid hormone-1-34 - Entera Bio; PTH oral - Entera Bio; PTH-1-34 - Entera Bio

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Entera Bio
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypoparathyroidism
  • Phase I Osteoporosis

Most Recent Events

  • 18 Sep 2017 Teriparatide is still in phase II development for Hypoparathyroidism and phase I development for Osteoporosis (EnteraBio Ltd pipeline, September 2017)
  • 19 Sep 2016 Pharmacokinetic results from a phase I trial in Osteoporosis reported at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in Israel (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top